Your browser is no longer supported. Please, upgrade your browser.
AMRN Amarin Corporation plc monthly Stock Chart
AMRN [NASD]
Amarin Corporation plc
Index- P/E- EPS (ttm)-0.30 Insider Own0.50% Shs Outstand290.40M Perf Week338.16%
Market Cap3.60B Forward P/E- EPS next Y-0.06 Insider Trans0.00% Shs Float151.92M Perf Month350.91%
Income-84.20M PEG- EPS next Q-0.10 Inst Own38.30% Short Float6.88% Perf Quarter346.04%
Sales197.80M P/S18.21 EPS this Y45.20% Inst Trans-10.04% Short Ratio1.76 Perf Half Y292.41%
Book/sh-0.24 P/B- EPS next Y85.70% ROA-49.00% Target Price7.60 Perf Year276.90%
Cash/sh0.35 P/C35.20 EPS next 5Y35.40% ROE134.70% 52W Range2.35 - 12.47 Perf YTD209.23%
Dividend- P/FCF- EPS past 5Y29.10% ROI-154.70% 52W High2.73% Beta0.93
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin75.30% 52W Low445.11% ATR0.84
Employees241 Current Ratio1.40 Sales Q/Q16.40% Oper. Margin-35.30% RSI (14)95.57 Volatility11.46% 7.38%
OptionableYes Debt/Eq- EPS Q/Q-131.30% Profit Margin-46.30% Rel Volume20.45 Prev Close12.40
ShortableYes LT Debt/Eq- EarningsOct 31 BMO Payout- Avg Volume5.95M Price12.81
Recom1.60 SMA20263.92% SMA50313.94% SMA200285.69% Volume93,495,209 Change3.31%
Jun-27-17Resumed Cantor Fitzgerald Overweight
Oct-19-16Initiated Citigroup Buy $5
Oct-05-16Initiated Cantor Fitzgerald Buy $6
May-12-16Resumed Jefferies Buy
Mar-12-15Upgrade H.C. Wainwright Neutral → Buy $2.50 → $10
Apr-01-14Reiterated MKM Partners Neutral $1.50 → $2
Feb-24-14Reiterated MKM Partners Neutral $2.50 → $1.75
Jan-16-14Downgrade MKM Partners Buy → Neutral $2.50
Nov-08-13Reiterated MKM Partners Buy $5 → $2.50
Oct-30-13Initiated FBR Capital Mkt Perform $2
Oct-17-13Reiterated MKM Partners Buy $9 → $5
Oct-17-13Downgrade Canaccord Genuity Buy → Hold $10 → $3
Oct-17-13Downgrade Aegis Capital Buy → Hold
Mar-20-13Initiated Chardan Capital Markets Hold $8.50
Dec-10-12Reiterated Aegis Capital Buy $25 → $35
Dec-07-12Reiterated Aegis Capital Buy $25 → $35
Jul-12-11Initiated MKM Partners Buy $23
Apr-25-11Reiterated Wedbush Outperform $12 → $18
Apr-18-11Reiterated Canaccord Genuity Buy $11 → $18
Dec-29-10Reiterated Wedbush Outperform $7 → $10
Sep-25-18 10:00AM  Forget Tilray, These Two Biotech Stocks Have Far More Upside Motley Fool
09:24AM  Tuesdays Vital Data: General Electric Company, Snap and Amarin InvestorPlace
09:05AM  Amarin Bulls Turn Huge Profits on Significant Data Results TheStreet.com
08:30AM  The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: Amarin Corporation and AcelRx Pharmaceuticals ACCESSWIRE
Sep-24-18 09:00PM  Is It Time to Ditch Your Fish Oil Pill for This "Miracle" Medicine? Motley Fool +314.72%
08:07PM  Amarin Surges on Fish-Oil Drug Data The Wall Street Journal
04:55PM  The Big Party in Amarin Stock Is Just Getting Started InvestorPlace
04:33PM  Why Barrick Gold, Amarin, and California Resources Jumped Today Motley Fool
03:19PM  Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It TheStreet.com
03:15PM  Drug Stocks Rally Midday; Chinese Stocks Take a Hit Investing.com
02:43PM  Amarin Surges on Fish-Oil Drug Data The Wall Street Journal
02:40PM  Amarin's 475% Surge Leaves Its Holders Flush and Sellers Crushed Bloomberg
12:14PM  [$$] Surprise Heart Data Is Just the Beginning for Amarin The Wall Street Journal
12:06PM  Biotech News: Why Amarin Stock Is Going Gangbusters Today InvestorPlace
10:29AM  Fish-Oil Heart Medicine Is Rarest of Drug Breakthroughs Bloomberg
07:35AM  Amarin's stock rockets nearly 4-fold after positive trial results MarketWatch
07:33AM  Why Amarin Corporation Stock Is Exploding Higher Today Motley Fool
06:53AM  Amarin shares surge nearly 300% after fish oil capsule showed benefits to heart patients in trial CNBC
05:30AM  HLS Therapeutics Announces that Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint CNW Group
04:30AM  REDUCE-IT Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint GlobeNewswire
Sep-16-18 02:22PM  The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-12-18 09:21AM  REDUCE-IT Trial Primary Results Accepted for Presentation at 2018 Scientific Sessions of American Heart Association GlobeNewswire
Sep-11-18 11:31AM  What Does Amarin Corporation plcs (NASDAQ:AMRN) Ownership Structure Look Like? Simply Wall St.
Sep-08-18 08:10PM  Will Amarin Reward Patient Investors? Motley Fool
Sep-06-18 03:02PM  A New Deal Moves MannKind Back From the Brink Motley Fool
Sep-05-18 09:23AM  3 Biotech Stocks That Still Have Major Catalysts in September Motley Fool
Sep-03-18 12:42PM  Why Amarin Corporation Skyrocketed 23.9% in August Motley Fool
Sep-02-18 09:41AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings Benzinga
09:10AM  3 Biotech Stocks That Could Soar Next Week Motley Fool
Aug-26-18 11:00AM  Amarins REDUCE-IT Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results GlobeNewswire
Aug-21-18 08:15AM  New Research Coverage Highlights pdvWireless, Fortuna Silver Mines, Nordic American Tankers, Amarin, Himax Technologies, and Retrophin Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-16-18 08:44AM  Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation Motley Fool
Aug-14-18 05:54PM  Edited Transcript of AMRN earnings conference call or presentation 1-Aug-18 11:30am GMT Thomson Reuters StreetEvents
Aug-03-18 06:00AM  This Small-Cap Biotech Is Poised for Eye-Popping Gains Motley Fool
Aug-01-18 05:41AM  Amarin: 2Q Earnings Snapshot Associated Press +7.84%
05:00AM  Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations GlobeNewswire
Jul-26-18 08:48AM  Amarin Announces Approval for Vascepa® in United Arab Emirates GlobeNewswire
Jul-24-18 05:00AM  Amarin to Report Second Quarter 2018 Results and Host Conference Call on August 1, 2018 GlobeNewswire
Jul-13-18 07:31AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jul-11-18 10:00AM  Is Now the Perfect Time to Buy Amarin Corporation Stock? Motley Fool
Jul-02-18 07:05AM  Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-28-18 05:21PM  Why Amarin Corporation Zoomed 10% Higher Today Motley Fool +10.18%
05:00AM  Amarin Reports Last Patient Study Visit Has Occurred, an Important Step Towards Completion of REDUCE-IT Cardiovascular Outcomes Study GlobeNewswire
Jun-25-18 04:30PM  Real-World Data Supports Association Between High Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs in People with Diabetes Mellitus GlobeNewswire
Jun-22-18 08:40AM  Is the Options Market Predicting a Spike in Amarin (AMRN) Stock? Zacks
Jun-12-18 05:00AM  Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications GlobeNewswire
Jun-07-18 05:00AM  Amarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions GlobeNewswire
Jun-06-18 07:40AM  Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jun-04-18 07:30AM  Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks ACCESSWIRE
May-25-18 09:19AM  Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended Benzinga
May-24-18 04:35PM  Amarin Announces Patent Litigation Settlement Agreement with Teva GlobeNewswire
May-23-18 04:30PM  Amarin to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-21-18 08:48AM  Is the Options Market Predicting a Spike in Amarin (AMRN) Stock? Zacks -5.20%
May-09-18 04:05AM  Edited Transcript of AMRN earnings conference call or presentation 2-May-18 11:30am GMT Thomson Reuters StreetEvents
May-02-18 05:52AM  Amarin: 1Q Earnings Snapshot Associated Press
05:00AM  Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations GlobeNewswire
May-01-18 06:02AM  3 Stocks That Could Put Tesla's Returns to Shame Motley Fool
Apr-26-18 05:00AM  Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018 GlobeNewswire +6.72%
Apr-24-18 08:45AM  Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock? Zacks
Apr-23-18 05:00AM  Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer GlobeNewswire
Apr-13-18 08:20AM  New Research: Key Drivers of Growth for Amarin, Korea Electric Power, Star Bulk Carriers, 1-800 FLOWERS.COM, Clementia Pharmaceuticals, and Bank of Nova Scotia Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Apr-12-18 04:30PM  Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions GlobeNewswire
10:22AM  Moving Average Crossover Alert: Amarin (AMRN) Zacks
05:00AM  Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides GlobeNewswire
Apr-06-18 07:30AM  Wired News Amarins REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACE ACCESSWIRE
Apr-04-18 07:16PM  Boom-or-Bust News Is On Tap Soon for Amarin Motley Fool +7.85%
05:15AM  Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives GlobeNewswire
05:00AM  Amarins REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events GlobeNewswire
Apr-02-18 08:46AM  Implied Volatility Surging for Amarin (AMRN) Stock Options Zacks
06:00AM  7 Stocks for the Biotech Takeover Wave Investopedia
Mar-31-18 03:25AM  Edited Transcript of AMRN earnings conference call or presentation 27-Feb-18 12:30pm GMT Thomson Reuters StreetEvents
Mar-29-18 05:00AM  Amarin Sponsors Two Scientific Presentations Scheduled for National Kidney Foundation 2018 Spring Clinical Meetings GlobeNewswire
Mar-28-18 04:30PM  Amarin to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-27-18 04:30PM  Amarin Commemorates National Triglycerides Day on March 28 GlobeNewswire
Mar-21-18 05:00AM  Amarin Announces First Middle East Approval for Vascepa® GlobeNewswire
Mar-20-18 08:46AM  3 Stocks That Could Put Alibaba's Returns to Shame Motley Fool
Mar-16-18 08:10AM  New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-12-18 04:30PM  Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP) GlobeNewswire
04:30PM  Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs GlobeNewswire
Mar-09-18 07:18PM  Cramer's lightning round: I screwed up on Apache and won'... CNBC Videos
06:51PM  Cramer's lightning round: I screwed up on Apache and won't stop you from selling CNBC
Mar-05-18 04:35PM  Amarin Announces Closing of Underwriters Purchase of Additional Shares GlobeNewswire
08:50AM  Implied Volatility Surging for Amarin (AMRN) Stock Options Zacks
Mar-01-18 05:00AM  Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study GlobeNewswire
Feb-28-18 05:00AM  Amarin Sponsors Multiple Scientific Presentations Scheduled for 2018 American College of Cardiology Annual Scientific Session & Expo GlobeNewswire
Feb-27-18 05:41AM  Amarin reports 4Q loss Associated Press
05:00AM  Amarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations GlobeNewswire
Feb-20-18 04:30PM  Amarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018 GlobeNewswire
Jan-30-18 08:58AM  Amarin Prices Public Offering of American Depositary Shares GlobeNewswire
Jan-29-18 04:21PM  Amarin Corporation plc (ADR) (AMRN) Cashes Out; Shares Tumble SmarterAnalyst -6.09%
04:01PM  Amarin Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Jan-24-18 09:09AM  Heres Whats Moving Amarin Corporation and Puma Biotechnology Market Exclusive
08:51AM  Amarin (AMRN) Soars: Stock Adds 9.9% in Session Zacks
Jan-23-18 12:13PM  Why Amarin Corporation Stock Is Surging Today Motley Fool +9.90%
06:00AM  Amarins REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events GlobeNewswire
Jan-19-18 07:20AM  Wired News Amarin Initiates Clinical Development of VASCEPA in Mainland China ACCESSWIRE
Jan-17-18 06:00AM  Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China GlobeNewswire
Jan-04-18 05:32PM  Company Update (NASDAQ:AMRN): Amarin Corporation plc Provides Preliminary 2017 Results and Provides 2018 Outlook SmarterAnalyst
04:30PM  Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook GlobeNewswire
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.